Endo International — Q4 2021 Earnings Presentation
21 slides from Endo International's earnings presentation, Feb 28, 2022
Slide 1: Q4 and FY 2021 Earnings Report
Q4 and FY 2021 Earnings Report endo.com ©2022 Endo International plc or one of its affiliates. All rights reserved
Slide 2: Forward Looking Statements; Non-GAAP Financial Measures
Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1 995 and Canadian securities legislation. Statements including words such as “believes,” “expects,” “anticipates,” “int
Slide 3: Today's Agenda
Today’s Agenda Strategic Priorities Business Performance Pipeline Update Financial Results & Guidance Q&A 2 ©2022 Endo International plc or one of its affiliates. All rights reserved
Slide 4: Endo: A Diversified Specialty Pharmaceutical Company
Endo: A Diversified Specialty Pharmaceutical Company Our Vision Helping everyone we serve live their best life. Our Mission We develop and deliver life-enhancing products through focused execution. Our Strategic Priorities Expand & Reinvent How Be A Force Enhance Our We Work For Good Portfolio 3 ©20
Slide 5: Q4 and FY 2021 Snapshot
Q4 and FY 2021 Snapshot Revenues (U.S. $M) Q4 2021 Q4 2020 FY 2021 FY 2020 Branded Pharmaceuticals $228 $225 $ 894 $782 Sterile Injectables $319 $332 $1,266 $1,239 Generic Pharmaceuticals $218 $180 $741 $783 International Pharmaceuticals $ 24 $ 23 $93 $99 Total Revenues $789 $760 $2,993 $2,903 Adjus
Slide 6: Q4 2021 Performance
Q4 2021 Performance (Reported Revenues in $ millions) Branded Pharmaceuticals $225m $228m Y-o-Y Change $67m Despite increasing COVID-19 driven $71m Branded Pharm. 2% pressures, XIAFLEX® revenue grew driven by Specialty Products 4% increased net price and improving patient $161m demand compared to
Slide 7: Q4 2021 Performance
Q4 2021 Performance (Reported Revenues in $ millions) Generic Pharmaceuticals Y-o-Y Change Increase primarily due to 2021 product Generic launches, including varenicline tablets, only $218m Pharmaceuticals 21% $180m FDA approved generic of CHANTIX®, and lubiprostone capsules, first authorized gene
Slide 8: Varenicline: Poised to Optimize Opportunity
Varenicline: Poised to Optimize Opportunity Varenicline Molecule (TRx) Currently, only FDA-approved generic 300,000 Chantix® Shortages on the market 250,000 Start 200,000 Endo Enters Vertically integrated from API to final 150,000 finished product 100,000 Expanding capacity to meet demand 50,0
Slide 9: XIAFLEX: Maximizing for Long Term Value
XIAFLEX®: Maximizing for Long Term Value Current On-market Indications Peyronie’s Disease Condition awareness campaign: specific request for XIAFLEX® honored 65-70% of the time by HCP Opportunity to further “medicalize” the situation Dupuytren’s Contracture New unbranded 2022 campaign featurin
Slide 10: QWO: Focus on Creating Cornerstone Cellulite Treatment
QWO®: Focus on Creating Cornerstone Cellulite Treatment 2021: Building the foundation Ongoing Studies & Data Generation >1,800 > 7.3B 224 CCH injected in grid pattern in non- obese subjects with mild to Final results expected in Q1’22 moderate cellulite of the Certified Offices Media Impressions thi
Slide 11: Sterile Injectables and Generics Pipeline
Sterile Injectables and Generics Pipeline Reflects Focus on More Durable and Differentiated Sterile Products Sterile Injectable Product Continuum Pending Filings – by Product Category 18% Generic Retail Less More differentiated differentiated Traditional Long Acting Drug/Device 18% Generic Specialty
Slide 12: Vasostrict RTU bottles: Improved efficiency, reduced labor
Launched Vasostrict® RTU bottles: Improved efficiency, reduced labor Multiple Steps: One Step: Draw, Dilute, Mix, Spike Spike RTU product adoption can free up pharmacy and nursing to complete other tasks Decreased risk for preparation or contamination errors Enhanced medication safety for pati
Slide 13: Q4 2021: Financial Results (Continuing Operations)
Q4 2021: Financial Results (Continuing Operations*) US GAAP Non-GAAP (U.S. $, and Shares in millions) Q4 ’21 Q4 ’20 Q4 ’21 Q4 ’20 Total Revenues, net $789 $760 $789 $760 Gross Margin % 60.6% 51.4% 72.1% 66.4% Operating (Loss) Income $(419) $131 $367 $326 (Loss) Income $(557) $141 $200 $176 Effective
Slide 14: Q1 2022 Financial Guidance (Continuing Operations)
Q1 2022 Financial Guidance (Continuing Operations*) Measure Q1’2022 Total Revenues, net $595M – $635M Adjusted EBITDA $240M – $260M Adjusted Diluted Net Income per Share $0.35 – $0.45 The Company’s Q1’22 Financial Guidance is Based on the Following Assumptions: Measure Q1’2022 Adjusted Gross Margin
Slide 15: Q1 2022 Segment Revenue Assumptions
Q1 2022 Segment Revenue Assumptions Segment Q1’22 vs. Q1’21 % Revenue Change Branded Pharmaceuticals Mid to high single digit decline Sterile Injectables Mid 20’s to low 30’s decline Generic Pharmaceuticals In-line to low single digit decline International Pharmaceuticals Mid single digit decline To
Slide 16: Cash Flow Prior to Debt Payments
Cash Flow Prior to Debt Payments Q1 2022 Guidance Q1 2021 2021 2020 (Current) YTD US $M Actual Actual Low High Actual Adjusted EBITDA $1,481 $1,396 $240 $260 $365 Cash Interest ($541) ($535) ~($80) ($105) Changes in Net Working Capital $19 ($115) ~$0 $43 Cash Taxes, Net Refund (Payments) $48 $20 ~($
Slide 17: Our Strategic Priorities
Our Strategic Priorities Expand & Reinvent How Be A Force Enhance Our We Work For Good Portfolio We are investing to build We are embracing the We are committed to a more differentiated and future by accelerating the adoption of more durable portfolio that new ways of working to sustainable practice
Slide 18: Q&A
Q&A 17 ©2022 Endo International plc or one of its affiliates. All rights reserved
Slide 19: Appendix
Appendix 18 ©2022 Endo International plc or one of its affiliates. All rights reserved
Slide 20: Cash Conversion Cycle
Cash Conversion Cycle We use days sales outstanding (DSO), days inventory outstanding (DIO) and days payable outstanding (DPO), the sum of which is the cash conversion cycle, to evaluate our working capital performance. The following table summarizes the details of the financial metrics used to calc
Slide 21: Thank you
Thank you endo.com ©2022 Endo International plc or one of its affiliates. All rights reserved